Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Key facts
- Who runs it
- The University of Texas Medical Branch, Galveston
- Where
- Galveston, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 618 people enrolled
- Started
- 18 Jan 2023
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 9-valent HPV vaccine, 2 doses alternate timing
- 9-valent HPV vaccine, 3 doses standard timing
- Record updated
- 6 November 2026
Who can take part
- Age
- 27 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Females 27-45 years old
- Ability to give informed consent
- Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record
- Reliable telephone access for the duration of the project
- Can read and speak in either English or Spanish
- Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc
- Reports consistent use of reliable birth control and plans to continue its use through study month 13
Who cannot take part
- Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study
- Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date
- Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- History of splenectomy
- Known allergies to any vaccine components, including aluminum, yeast or Benzonase
- History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- History of >10 sexual partners in their lifetime at time of enrollment
- Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care
- Plans to move out of the Galveston/Houston area in the 13 months following study entry
Where in United States
- University of Texas Medical BranchGalveston, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
The 2 groups in the trial
- Females, 3-dose standardExisting treatment, for comparison
Three doses of the 9-valent HPV vaccine to be administered to the comparison group (27-45 years of age) at 0, 2, and 6 months.
Treatment: 9-valent HPV vaccine, 3 doses standard timing
- Females, 2-dose alternativeTreatment being tested
Two doses of the 9-valent HPV vaccine to be administered to the experimental group (27-45 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
Treatment: 9-valent HPV vaccine, 2 doses alternate timing
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age
- Publications
- Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.The Cochrane database of systematic reviews, 2025
- Record updated
- 6 November 2026